AU2013286876B2 - Methods for treating, diagnosing and/or monitoring progression of oxo associated states - Google Patents

Methods for treating, diagnosing and/or monitoring progression of oxo associated states Download PDF

Info

Publication number
AU2013286876B2
AU2013286876B2 AU2013286876A AU2013286876A AU2013286876B2 AU 2013286876 B2 AU2013286876 B2 AU 2013286876B2 AU 2013286876 A AU2013286876 A AU 2013286876A AU 2013286876 A AU2013286876 A AU 2013286876A AU 2013286876 B2 AU2013286876 B2 AU 2013286876B2
Authority
AU
Australia
Prior art keywords
subject
oxoprotective
agent
associated state
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013286876A
Other languages
English (en)
Other versions
AU2013286876A1 (en
Inventor
Jay Pravda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2013286876A1 publication Critical patent/AU2013286876A1/en
Application granted granted Critical
Publication of AU2013286876B2 publication Critical patent/AU2013286876B2/en
Priority to AU2017206229A priority Critical patent/AU2017206229A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7004—Stress
    • G01N2800/7009—Oxidative stress
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/20—Oxygen containing
    • Y10T436/206664—Ozone or peroxide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2013286876A 2012-07-03 2013-07-02 Methods for treating, diagnosing and/or monitoring progression of oxo associated states Ceased AU2013286876B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2017206229A AU2017206229A1 (en) 2012-07-03 2017-07-20 Methods for treating, diagnosing and/or monitoring progression of oxo associated states

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261667719P 2012-07-03 2012-07-03
US61/667,719 2012-07-03
US201261691787P 2012-08-21 2012-08-21
US61/691,787 2012-08-21
US201361748698P 2013-01-03 2013-01-03
US61/748,698 2013-01-03
PCT/US2013/049087 WO2014008273A2 (en) 2012-07-03 2013-07-02 Methods for treating, diagnosing and/or monitoring progression of oxo associated states

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017206229A Division AU2017206229A1 (en) 2012-07-03 2017-07-20 Methods for treating, diagnosing and/or monitoring progression of oxo associated states

Publications (2)

Publication Number Publication Date
AU2013286876A1 AU2013286876A1 (en) 2015-02-26
AU2013286876B2 true AU2013286876B2 (en) 2017-04-20

Family

ID=49882592

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2013286876A Ceased AU2013286876B2 (en) 2012-07-03 2013-07-02 Methods for treating, diagnosing and/or monitoring progression of oxo associated states
AU2017206229A Abandoned AU2017206229A1 (en) 2012-07-03 2017-07-20 Methods for treating, diagnosing and/or monitoring progression of oxo associated states

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2017206229A Abandoned AU2017206229A1 (en) 2012-07-03 2017-07-20 Methods for treating, diagnosing and/or monitoring progression of oxo associated states

Country Status (7)

Country Link
US (1) US20150174160A1 (enExample)
EP (1) EP2866565A4 (enExample)
JP (1) JP6509112B2 (enExample)
CN (1) CN104582490A (enExample)
AU (2) AU2013286876B2 (enExample)
CA (1) CA2915793A1 (enExample)
WO (1) WO2014008273A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210239678A1 (en) * 2018-04-19 2021-08-05 StickyCell Pty Ltd Leukocyte recruitment in infectious disease
US11406607B2 (en) 2018-05-24 2022-08-09 University Of Florida Research Foundation, Inc. Compositions, methods of treatment, and containers including compositions
AU2023312830A1 (en) * 2022-07-27 2025-02-20 Redox Bioscience LLC Methods and compounds for treating ulcerative colitis, systemic lupus erythematosus, sepsis, and post-sepsis syndrome
JP2025531018A (ja) 2022-09-14 2025-09-19 ビオグノシス アーゲー 薬物標的滞留時間を決定し、最適な薬物－標的候補を選択する方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090181081A1 (en) * 2002-06-19 2009-07-16 Gabriel Gojon-Romanillos Systemic Treatment of Pathological Conditions Resulting From Oxidative Stress and/or Redox Imbalance
US20100112088A1 (en) * 2003-08-29 2010-05-06 Jay Pravda Materials and methods for treatment of disorders associated with oxidative stress
US20100184728A1 (en) * 2003-08-29 2010-07-22 Therapeutic Research Llc Materials and methods for treatment and diagnosis of disorders associated with oxidative stress

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9309387D0 (en) * 1993-05-06 1993-06-16 Wellcome Found Nitric oxide scavengers
AU682894B2 (en) * 1993-10-28 1997-10-23 Institut National De La Recherche Agronomique Composition based on amino acids intended for the treatment of sepsis or of an attack bringing about an inflammatory reaction, in animals and man
US5990153A (en) * 1997-05-05 1999-11-23 Wood; John G. Ultrasonicated α-lipoic acid solutions for attenuating microvascular injury
US6712802B1 (en) * 1997-11-04 2004-03-30 Charles B. Cairns Metabolic therapy directed at electron transport
DK1063228T5 (da) * 1998-03-09 2009-06-15 Takeda Pharmaceutical Cycloalkenderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf
US20030190368A1 (en) * 1998-03-11 2003-10-09 Roland Stoughton Methods of diagnosis and triage using cell activation measures
FR2791571B1 (fr) * 1999-04-02 2002-10-04 Sod Conseils Rech Applic Association inhibiteur(s) de no synthase et antioxydant(s) metabolique(s)
US7758893B2 (en) * 2001-07-27 2010-07-20 N.V. Nutricia Enteral compositions for the prevention and/or treatment of sepsis
EP1302115A1 (fr) * 2001-10-16 2003-04-16 Societe Des Produits Nestle S.A. Utilisation de cystathionine
DE10151764A1 (de) * 2001-10-19 2003-05-08 Basf Ag Kombination von Liponsäure und Glutamin in Lebens- und Arzneimitteln
WO2003104178A1 (en) * 2002-06-07 2003-12-18 Cortical Pty Ltd Napththalene derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (mif)
US20070270350A1 (en) * 2003-12-23 2007-11-22 Musc Foundation For Research Development Methods and Compositions for the Prevention and Treatment of Inflammatory Diseases or Conditions
FR2894482A1 (fr) * 2005-12-14 2007-06-15 Galderma Sa Utilisation d'une composition comprenant une association d'hydroquinone,d'acetonide de fluocinolone et de tretinoine, dans le traitement d'l'hyperpigmentation de la peau suite au psoriasis ou a l'eczema
WO2009154800A2 (en) * 2008-06-21 2009-12-23 Webb-Waring Institute Compositions and methods for treating lung disorders
CA2785633C (en) * 2009-12-28 2014-07-15 N.V. Perricone Llc Topical acyl glutathione formulations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090181081A1 (en) * 2002-06-19 2009-07-16 Gabriel Gojon-Romanillos Systemic Treatment of Pathological Conditions Resulting From Oxidative Stress and/or Redox Imbalance
US20100112088A1 (en) * 2003-08-29 2010-05-06 Jay Pravda Materials and methods for treatment of disorders associated with oxidative stress
US20100184728A1 (en) * 2003-08-29 2010-07-22 Therapeutic Research Llc Materials and methods for treatment and diagnosis of disorders associated with oxidative stress

Also Published As

Publication number Publication date
AU2017206229A1 (en) 2017-08-03
AU2013286876A1 (en) 2015-02-26
JP6509112B2 (ja) 2019-05-08
WO2014008273A3 (en) 2014-02-27
US20150174160A1 (en) 2015-06-25
EP2866565A4 (en) 2016-04-13
CA2915793A1 (en) 2014-01-09
JP2015523364A (ja) 2015-08-13
EP2866565A2 (en) 2015-05-06
CN104582490A (zh) 2015-04-29
WO2014008273A2 (en) 2014-01-09

Similar Documents

Publication Publication Date Title
JP5303465B2 (ja) 液体カルコゲナイド組成物ならびにそれを製造および使用する方法
WO2005017094A2 (en) N-acetyl compositions as adjunct therapy for treatment and prevention of cysteine/glutathione deficiency
Rahman et al. The role of host-generated H2S in microbial pathogenesis: new perspectives on tuberculosis
AU2017206229A1 (en) Methods for treating, diagnosing and/or monitoring progression of oxo associated states
ES3026756T3 (en) Bis-choline tetrathiomolybdate for treating wilson disease
US20100112088A1 (en) Materials and methods for treatment of disorders associated with oxidative stress
HK74697A (en) Pharmaceutical therapeutic use of glutathione derivatives
Milliner Cystinuria
du Preez et al. N‐Acetylcysteine and other sulfur‐donors as a preventative and adjunct therapy for COVID‐19
JP2010529197A5 (enExample)
Bocedi et al. Trypanothione efficiently intercepts nitric oxide as a harmless iron complex in trypanosomatid parasites
JP2010529197A (ja) 酸化的ストレス関連疾患の治療および診断のための材料および方法
EP3316877B1 (en) Ado-resistant cysteamine analogs and uses thereof
KR20160070154A (ko) 미토콘드리아병을 치료하기 위한 시스테아민 및 이의 유도체의 용도
JP2019501226A (ja) 急性肝不全及び他の肝毒性状態を治療及び／又はこれらから保護するための方法及び製剤
US20250325503A1 (en) New use of n,n-bis-2-mercaptoethyl isophthalamide
AU2005318832B2 (en) Therapeutic nutrient compositions or combinations and methods of their use
WO2023159060A1 (en) Compositions and methods for the treatment of coronavirus diseases
US20250009692A1 (en) Micronutrient composition to prevent and reverse protein glycation during oxidative stress in human
US20060111284A1 (en) Method for treating cancer
WO2023159057A1 (en) Compositions and methods for the treatment of human immunodeficiency virus
CN111228263A (zh) 乙基甲基羟基吡啶苹果酸盐或其药物组合物，预防和/或治疗ⅱ型糖尿病的用途
UA15076U (en) Method for treating preclinical disorders of carbohydrate metabolism in patients with lung tuberculosis

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired